R. Somers

Second cancer risk following Hodgkin's disease: a 20-year follow-up study.

Flora E. van Leeuwen, Willem J. Klokman, Anton Hagenbeek et al. · Journal of Clinical Oncology · 1994 · 447 citations

Long-Term Risk of Second Malignancy in Survivors of Hodgkin’s Disease Treated During Adolescence or Young Adulthood

Flora E. van Leeuwen, Willem J. Klokman, Mars B. vanʼt Veer et al. · Journal of Clinical Oncology · 2000 · 437 citations

Second cancer risk following testicular cancer: a follow-up study of 1,909 patients.

Flora E. van Leeuwen, Anne M. Stiggelbout, Alexandra W. van den Belt‐Dusebout et al. · Journal of Clinical Oncology · 1993 · 252 citations

Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas

Vivien Bramwell, Henning T. Mouridsen, Armando Santoro et al. · European Journal of Cancer and Clinical Oncology · 1987 · 242 citations

Surgical Oncology, Cyclophosphamide Versus Ifosfamide, Medicine +6

Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.

Flora E. van Leeuwen, A.M.J. Chorus, Alexandra W. van den Belt‐Dusebout et al. · Journal of Clinical Oncology · 1994 · 193 citations